Bone Biologics Corp (BBLGW) Accumulated Depreciation (2014 - 2017)

Bone Biologics (BBLGW) has reported Accumulated Depreciation for 4 consecutive years, with $357.0 the latest figure, recorded in Q4 2017.

• In Q4 2017, Accumulated Depreciation rose 36.78% year-over-year to $357.0; the TTM figure through Dec 2017 stood at $357.0 (up 36.78% YoY), while the FY2017 annual figure was $357.0, up 36.78% from the prior year.
• Accumulated Depreciation improved to $357.0 in Q4 2017 per BBLGW's latest filing, from $333.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $3982.0 in Q4 2015 and bottomed at $141.0 in Q1 2016.
• Historically, Accumulated Depreciation has averaged $816.54 across 4 years, with a median of $309.0 in 2017.
• Annual changes were most pronounced in 2015 — Accumulated Depreciation jumped 1322.14% — and 2016, when it plunged 93.45%.
• Bone Biologics' Accumulated Depreciation stood at $280.0 in 2014, then surged by 1322.14% to $3982.0 in 2015, then slumped by 93.45% to $261.0 in 2016, then jumped by 36.78% to $357.0 in 2017.
• Business Quant data shows BBLGW's Accumulated Depreciation at $357.0 in Q4 2017, $333.0 in Q3 2017, and $309.0 in Q2 2017.